Suppliers and packagers for generic pharmaceutical drug: TRIENTINE TETRAHYDROCHLORIDE

TRIENTINE TETRAHYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760	NDA	Orphalan SA	81802-001-72	9 CARTON in 1 CARTON (81802-001-72) / 1 BLISTER PACK in 1 CARTON (81802-001-08) / 8 TABLET, FILM COATED in 1 BLISTER PACK	2022-09-14

Suppliers and packagers for generic pharmaceutical drug: TRIENTINE TETRAHYDROCHLORIDE

Last updated: May 25, 2026

Trientine Tetrahydrochloride Suppliers List: Manufacturers, API Sources, and Contract Packaging

Trientine tetrahydrochloride is sourced through a mix of bulk active pharmaceutical ingredient (API) manufacturers and specialty chemical/API suppliers that support pharma-grade material, plus a downstream base of distributors and relabelers. The supply chain is typically segmented into: (1) API manufacture of trientine salt chemistry, (2) finished-dose and excipient supply for branded generics, and (3) distribution of bulk API to formulators and contract manufacturers.

Who supplies trientine tetrahydrochloride API to pharma?

API suppliers for trientine tetrahydrochloride generally market the material as “trientine tetrahydrochloride” (salt form) and/or as “trientine” with defined equivalent salt content. Common commercial patterns are:

• Pharma-grade API offered in drum/IBC formats with COAs, GMP documentation, and DMF/EDMF linkages where available.
• Multi-grade supply lines (research, intermediate, and pharmaceutical grade) with pharmaceutical-grade routed through GMP manufacturing and validated analytical release.
• Export-oriented supply where packaging, labeling, and import documentation are handled by specialized distributors.

Which companies sell trientine tetrahydrochloride bulk API (GMP) and what do they typically provide?

Key seller archetypes:

• API manufacturers (GMP sites): Produce trientine tetrahydrochloride from trientine precursor chemistry and salt formation/purification steps; provide batch documentation suitable for NDA/ANDA comparability work.
• Specialty chemical/API distributors: Source from GMP manufacturers and resell with distributor COAs plus upstream manufacturing statements.
• CMO-controlled supply: Some contract manufacturers qualify and control API supply through vendor qualification and incoming testing, using approved supplier lists.

How to assess trientine tetrahydrochloride supplier quality for regulatory filings

Procurement teams typically screen suppliers on:

• GMP status: Whether API is manufactured under GMP and whether the site supports regulatory submissions.
• Documentation: COA format, impurity profiles, residual solvent compliance where relevant, and traceability.
• Change control: Ability to support post-approval changes with prior notifications and comparability packages.
• Analytical package: Release method coverage, impurity method validation readiness, and stability program data.

What supplier documentation matters most for ANDAs and clinical development?

For an ANDA or clinical supply chain, procurement normally requires:

• Batch-specific COAs (assay, related substances, water/LOD as applicable, particle attributes if specified).
• Any supporting regulatory dossier references (DMF holder support or EDMF linking where used).
• Evidence that the supplier can support material used in exhibits for bioequivalence, stability, and process validation.

What are the main finished-dose manufacturing supply channels that use trientine tetrahydrochloride?

Trientine tetrahydrochloride is used in oral solid dosage formulations for Wilson disease and related copper overload indications. Finished-dose supply channels typically include:

• Branded manufacturers that internally manage API sourcing.
• Generic manufacturers that qualify an API supplier and file with an established API grade.
• Contract manufacturers that procure API on behalf of the finished-dose marketer and manage ongoing sourcing continuity.

Do contract manufacturing organizations (CMOs) control trientine API sourcing?

Yes, in many cases. CMOs that run oral solids often:

• Pre-qualify a vendor list for trientine tetrahydrochloride.
• Require incoming testing and may restrict procurement to approved lots.
• Implement redundancy across suppliers to mitigate supply disruption risk.

When do trientine tetrahydrochloride supply shortages affect generic entry?

Supply risk materializes when:

• One API site becomes capacity constrained.
• Impurity control tightens due to new analytical methods at the supplier or customer.
• Regulatory batch rejections occur due to analytical drift or documentation gaps.

What patent and exclusivity constraints affect API sourcing or finished-dose procurement?

Supplier selection is usually independent of patent barriers at the API level but can be downstream constrained by:

• Finished-dose formulation or manufacturing-process patents that tie a specific route or grade to the marketed product.
• Data exclusivity or listing constraints indirectly affecting which formulations can be launched first.
• Licensing terms in some cases if a supplier’s material is tied to a specific DMF or regulatory strategy.

How many suppliers typically exist for trientine tetrahydrochloride?

The market is usually characterized by a limited number of GMP API sources and a larger number of distributors. The supplier count can vary by geography and by whether customers require specific documentation for filings.

Which geographies supply trientine tetrahydrochloride most often?

Common patterns:

• India and China: frequently host multiple generic chemical/API producers with export-oriented pharma supply.
• Europe: typically has fewer direct API sellers but more distributor and contract manufacturing capacity.
• United States: often relies on import or distributor channels for API unless a specific supplier is established for local filings.

What generic entry risks exist for trientine tetrahydrochloride finished products due to supply sourcing?

Main risks:

• API availability gaps during transfer-of-supply qualification.
• Lot-to-lot impurity profile variance affecting formulation performance and stability.
• Extended qualification timelines if regulatory requirements force re-testing or requalification.

What formulation types require special trientine tetrahydrochloride sourcing controls?

Key product drivers:

• Oral solid tablets/capsules require consistent particle properties and impurity levels to maintain dissolution and stability specs.
• Dose strength consistency may be sensitive to assay normalization in salt-based materials.

How does trientine tetrahydrochloride compare with “trientine” and why that matters for suppliers?

Trientine tetrahydrochloride is a defined salt form; “trientine” equivalents used in supply contracts must be normalized to:

• assay basis (mg salt vs mg trientine equivalent),
• water content assumptions,
• impurity definition across supplier specifications.

Key Takeaways

• Trientine tetrahydrochloride supply is dominated by a small set of GMP-capable API manufacturers, with additional distributor and relabeler layers.
• Supplier qualification for pharma use hinges on GMP status, impurity/analytical package, and ability to support regulatory filings and change control.
• Generic and finished-dose launch timing can be constrained by API lot availability, impurity drift, and requalification timelines.

FAQs

1. How do I verify if a supplier can provide trientine tetrahydrochloride under GMP for ANDA use?
2. What COA items should be mandatory for trientine tetrahydrochloride API release?
3. Do distributors of trientine tetrahydrochloride provide traceability to the originating GMP API site?
4. What differences in specs (assay basis, salt form normalization) can cause formulation failure with trientine tetrahydrochloride?
5. How should supply continuity be structured when qualifying a second trientine tetrahydrochloride supplier for oral solids?

References (APA)

1. No sources were provided in the prompt.